Equine Serum Amyloid A (SAA) Recombinant

• Description:

  Equine Serum Amyloid A (SAA) Recombinant_x000D_ Catalog number: B2016377_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 ug_x000D_ Molecular Weight or Concentration: 13580 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -20 °C_x000D_ Keywords: Recombinant equine serum amyloid A (SAA)_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Jacobsen S, Ladefoged S, Berg LC. Production of serum amyloid A in equine articular chondrocytes and fibroblast-like synoviocytes treated with proinflammatory cytokines and its effects on the two cell types in culture Am J Vet Res. 2016 Jan;77(1):50-8._x000D_ 2: Lucassen A, Finkler-Schade C, Schuberth HJ. A Saccharomyces cerevisiae Fermentation Product (Olimond BB) Alters the Early Response after Influenza Vaccination in Racehorses Animals (Basel). 2021 Sep 18;11(9):2726._x000D_ 3: Sasaki K, Ma Z, Okazaki K, Khatlani TS, Okuda M, Kajikawa T, Onishi T. Characterization of monoclonal antibodies specific for feline serum amyloid (SAA) protein Hybridoma. 2001 Apr;20(2):103-8._x000D_ 4: Andersen SA, Petersen HH, Ersbøll AK, Falk-Rønne J, Jacobsen S. Vaccination elicits a prominent acute phase response in horses Vet J. 2012 Feb;191(2):199-202._x000D_ 5: Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens Exp Hematol. 2006 Jul;34(7):826-31._x000D_ 6: Piaggio G, Podestá M, Pitto A, Pittaluga GB, Isaza A, Benvenuto F, Bruno B, Bacigalupo A. Comparable TNF-alpha, IFN-gamma and GM-CSF production by purified normal marrow CD3 cells in response to horse anti-lymphocyte and rabbit antithymocyte globulin Eur J Haematol. 1998 Apr;60(4):240-4._x000D_ 7: Christensen MB, Sørensen JC, Jacobsen S, Kjelgaard-Hansen M. Investigation of the solubility and the potentials for purification of serum amyloid A (SAA) from equine acute phase serum--a pilot study BMC Res Notes. 2013 Apr 16;6:152._x000D_ 8: Hultén C, Tulamo RM, Suominen MM, Burvall K, Marhaug G, Forsberg M. A non-competitive chemiluminescence enzyme immunoassay for the equine acute phase protein serum amyloid A (SAA) -- a clinically useful inflammatory marker in the horse Vet Immunol Immunopathol. 1999 May;68(2-4):267-81._x000D_ 9: Hultén C, Sandgren B, Skiöldebrand E, Klingeborn B, Marhaug G, Forsberg M. The acute phase protein serum amyloid A (SAA) as an inflammatory marker in equine influenza virus infection Acta Vet Scand. 1999;40(4):323-33._x000D_ 10: Jacobsen S, Vinther AM, Kjelgaard-Hansen M, Nielsen LN. Validation of an equine serum amyloid A assay with an unusually broad working range BMC Vet Res. 2019 Dec 19;15(1):462. _x000D_ _x000D_ Products Related to Equine Serum Amyloid A (SAA) Recombinant can be found at Biofluids

• Short Description:

  Catalog Number: B2016377 (50 ug)_x000D_ Equine Serum Amyloid A (SAA) Recombinant is a high quality acute-phase protein that is produced in response to inflammation or infection in horses. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3